San Diego's Amplyx Pharmaceuticals boosted its Series B fundraise to $49.2 million and expanded its executive ranks, on pace to take its lead antifungal treatment into human trials this year.
Imagine a drug that could clear away "senescent" cells and make the life span allotted to you healthier, absent many of the myriad diseases that can accumulate with age. Some investigators have been working on that subject for more than a decade, and now a biotech is being launched to see if it can make that dream a reality.
LAM Therapeutics, a biotech co-founded by Yale University entrepreneur Jonathan Rothberg, raised $40 million to fund its work on an early-stage pipeline of treatments for rare diseases and cancer.
The new French biotech Enyo Pharma has raised a good chunk of money in its first round of financing as it looks to start human testing for a potential hepatitis B cure.
Cambridge, U.K.'s Mission Therapeutics raised £60 million ($86 million) in equity to fund its work in a novel biological pathway, uniting high-profile investors Imperial Innovations and Woodford Patient Capital Trust in the round.
Eight months after wrapping its first venture round with a $30 million bankroll, Cambridge, MA-based Spero Therapeutics has gone back to the well for $30 million more.
The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.
The French government is planning to triple the size of its biotech investment fund after the industry balked at the initial proposal. Officials now intend to hive off €340 million ($380 million) for the fund, more than three times the amount earmarked when they first floated the idea last year.
Adicet Bio has jumped out of stealth mode--more or less--with a $51 million A round and plans to combine two platform technologies into a next-gen approach on immunotherapies. The company was founded in 2014 and quietly launched a few months ago, says ex-Kite CEO and Adicet founder Aya Jakobovitz, who's been working as a partner at Orbimed while she assembled her new team.
Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $80 million. Now the Cambridge, MA, company has boosted its funding total to $92 million, extending its runway as it works through early-stage R&D.